Highbridge Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Highbridge Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$5.12M	–	449
2026 Q1	$5.12M	Sell	250,000 -150,000	-38%	-$2.9M	0.17%	92
2025 Q4	$8.61M	Buy	+400,000	New	+$8.43M	0.27%	66
2017 Q4	–	Sell	-20,326	Closed	-$922K	–	1941
2017 Q3	$922K	Buy	+20,326	New	+$812K	0.01%	626
2017 Q1	–	Sell	-30,809	Closed	-$845K	–	1689
2016 Q4	$845K	Sell	30,809 -7,410	-19%	-$298K	0.02%	591
2016 Q3	$2.35M	Buy	+38,219	New	+$1.16M	0.04%	407
2015 Q1	–	Sell	-68,173	Closed	-$987K	–	1572
2014 Q4	$987K	Buy	+68,173	New	+$1.15M	0.01%	654
2014 Q3	–	Sell	-61,915	Closed	-$1.84M	–	1354
2014 Q2	$1.84M	Buy	+61,915	New	+$1.96M	0.02%	439
2013 Q4	–	Sell	-11,026	Closed	-$520K	–	1305
2013 Q3	$520K	Buy	+11,026	New	+$425K	0.01%	869

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Highbridge Capital Management's SRPT Position: Q2 2026 in Review

Highbridge Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 250,000 shares — an estimated $5.12M sold.

Highbridge Capital Management first reported a position in SRPT in Q3 2013 and held it in 8 quarters. The position peaked at $8.61M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Highbridge Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Highbridge Capital Management sold 250,000 Sarepta Therapeutics shares in Q2 2026, an estimated $5.12M.
Highbridge Capital Management first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 8 quarters.
Highbridge Capital Management's Sarepta Therapeutics position peaked at $8.61M in Q4 2025.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Highbridge Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.